Bio tech company updates — 8/5/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
South Korean biotech company SK Biopharmaceuticals reported record second-quarter earnings, supported by strong U.S. sales of its epilepsy drug cenobamate (Xcopri). A separate CNN report highlighted South Korea-linked Biodance within the expanding biotech beauty sector.
Key Findings
- SK Biopharmaceuticals reported record second-quarter earnings. Revenue reached 247.4 billion won, up 40.3%, while U.S. sales of cenobamate rose 45.6%, according to Seoul Economic Daily.
- Biotech beauty continues to gain attention. CNN reported on a shift toward bio-based beauty ingredients and identified Biodance among companies discussed in the sector.
Details
SK Biopharmaceuticals
SK Biopharmaceuticals’ second-quarter revenue increased to 247.4 billion won, representing 40.3% growth, while U.S. sales of its epilepsy treatment cenobamate, marketed as Xcopri, increased 45.6%. The results were described as record earnings for the company.
The reported performance indicates that U.S. commercial sales of cenobamate were the principal growth driver identified in the available coverage.
Biotech beauty
CNN’s August 4 report described biotech beauty as a developing movement in which entrepreneurs are replacing fossil-fuel-derived ingredients with bio-based alternatives. The report included Biodance alongside Emma Lewisham and Réome in its coverage of the trend.
No additional company-specific financial or product-development details were available in the supplied fresh research results.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
